Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2024
Event: Entry into a Material Definitive Agreement (Amendment Number Three to the Merger Agreement with SEP Acquisition Corp.).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the amendment of a merger agreement.
Material Changes
- Outside Date Extension: The "Outside Date" for the Merger Agreement, which is the deadline after which either party may terminate the agreement if closing conditions are not met, has been extended from May 31, 2024, to June 30, 2024.
- Termination Rights: The Amendment grants the Company a unilateral right to terminate the Merger Agreement at any time upon written notice to SEP Acquisition Corp. (SEPA).
- No Other Changes: No other terms of the original Merger Agreement were altered.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The transaction remains subject to closing conditions, including a requirement that SEPA have at least $12.0 million at closing derived from non-redeemed Class A common stock and a private placement.
Risks and Contingencies:
- Failure to meet closing conditions, specifically the $12.0 million funding threshold.
- Delays in or inability to obtain necessary regulatory approvals.
- Inability to maintain the listing of SEPA's securities on Nasdaq post-transaction.
- General economic, business, and competitive factors.
- Termination of the agreement by either party (or unilaterally by the Company under the new amendment).
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to significant risks and uncertainties.
Important Facts for Investors to Verify
- Verify the current status of SEPA's funding to ensure the $12.0 million closing condition can be met by the new June 30, 2024 deadline.
- Review the definitive proxy statement and Form S-4 registration statement for detailed risk factors and transaction terms.
- Monitor for any further amendments or termination notices given the Company's new unilateral termination right.
- Confirm the status of regulatory approvals required to consummate the merger.